

Indian Express, Delhi

Thursday 6th February 2014, Page: 18

Width: 8.00 cms, Height: 5.77 cms, a4, Ref: pmin.2014-02-06.35.139

... sets aside ₹257.4 cr for impact of USFDA ban

NEW DELHI: Ranbaxy Laboratories has set aside Rs 257.4 crore towards the financial impact of a US ban on import of products made at its plant at Toansa.

In January, the US Food and Drug Administration (USFDA) had banned the import of Ranbaxy products from its Toansa

plant in Punjab due to deviations from good manufacturing practices.

"The company has made a provision of Rs 257.4 crore for the financial implication of USFDA ban on import of products from its Toansa plant," Ranbaxy said in a statement.

PTI

Sanjay